Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Pharma

Hangzhou, China, China

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company engaged in the development and manufacturing of pharmaceutical products.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

9 drugs in development

Phase 34

Phase 21

Phase 16

Preclinical1

By Therapeutic Area

top 2

Oncology

545%

Metabolic & Endocrine

327%

R&D Momentum

67/100

Pipeline Velocity

39/100

Trial Completion Rate

100/100

Pipeline Concentration

36/100

Pipeline Freshness

87/100

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Active, not recruiting

A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites

Earlier

Sep 5, 2026TrialA Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HDM2017 Combination Therapy in Participants With Advanced Colorectal Cancer

Sep 1, 2026TrialA Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy

Aug 29, 2026TrialA Randomized, Multicenter, Investigator-Blind Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Chinese Subjects With Plaque Psoriasis

Aug 27, 2026TrialA Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

Aug 25, 2026TrialA Randomized, Double-blind, Placebo-controlled, Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous (SC) Doses of HDM1005 Injection in Overweight or Obese Subjects

Aug 22, 2026TrialA Phase 3 Multicenter, Randomized, Parallel Group, Double Blind, Vehicle-controlled Study of the Efficacy and Safety of Roflumilast Foam 0.3% (ZORYVE®) in Trial Participants With Seborrheic Dermatitis

Jul 14, 2026TrialA Phase Ib/III Clinical Trial to Evaluate HDM2005 in Combination Therapy for Patients With Relapsed/Refractory Mantle Cell Lymphoma

4 more events

Jul 7, 2026TrialA Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 3 Clinical Study To Evaluate The Efficacy and Safety Of Roflumilast Cream 0.3% (Zoryve®) in the Treatment of Plaque Psoriasis In China

Mar 27, 2026TrialA Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Feb 24, 2026TrialA Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Nov 30, 2025TrialGanagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

HQHangzhou, China, China

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Metabolic & Endocrine(3 drugs)

—

Metabolic & Endocrine(3 drugs)

Oncology(5 drugs)

—

Oncology(5 drugs)

Unknown / Other(3 drugs)

—

Unknown / Other(3 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)